BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17846598)

  • 1. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL).
    Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Leung N; Gastineau DA
    Bone Marrow Transplant; 2007 Nov; 40(10):989-93. PubMed ID: 17846598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization.
    Gertz MA; Gastineau DA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Dingli D; Leung N; Wolf RC; Hogan WJ; Buadi FK
    Bone Marrow Transplant; 2011 Jul; 46(7):956-61. PubMed ID: 20972466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.
    Thompson JM; Carlton P; Akard LP; Dugan MJ; Jansen J
    Transfusion; 2009 Mar; 49(3):548-54. PubMed ID: 19040494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.
    Kumar S; Dispenzieri A; Lacy MQ; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2001 Aug; 28(4):381-5. PubMed ID: 11571511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.
    Olivieri A; Scortechini I; Capelli D; Montanari M; Lucesole M; Gini G; Troiani M; Offidani M; Poloni A; Masia MC; Raggetti GM; Leoni P
    Bone Marrow Transplant; 2004 Oct; 34(8):693-702. PubMed ID: 15300235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
    Fernández de Larrea C; Cibeira MT; Rovira M; Rosiñol L; Esteve J; Bladé J
    Eur J Haematol; 2008 Feb; 80(2):182-4. PubMed ID: 18081703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
    Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
    Musto P; Scalzulli PR; Terruzzi E; Rossini F; Iacopino P; Messina G; Guariglia R; Pietrantuono G; Villani O; D'Auria F; Falcone A; Sanpaolo G; Valvano MR; Pogliani EM; Morabito F
    Leuk Res; 2007 Nov; 31(11):1487-93. PubMed ID: 17320951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.
    Schmid I; Stachel D; Pagel P; Albert MH
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):438-44. PubMed ID: 18342786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing engraftment in autologous peripheral stem cell transplantation. The experience of a local Kuwaiti transplantation center.
    Alshemmari SH; Ameen RM; Gyrafas J; Alqallaf DA; Sajnani KP
    Saudi Med J; 2007 Jul; 28(7):1080-5. PubMed ID: 17603716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.